Aachen, Germany – Global pharmaceutical company Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will be taking on the role of Chief Commercial Officer (CCO) effective October 1st, 2024.
Adams has over two decades of experience in the pharmaceutical and healthcare industry. Since joining Grünenthal in 2017, he has been instrumental in driving the company’s transformational journey. As CSO, he has successfully led the development of a state-of-the-art R&D organization and redefined the company’s R&D strategy. Under his leadership, Grünenthal has also built an industry-leading pipeline focused on delivering innovative treatments for acute and chronic pain. Prior to his role as CSO, Adams served as Head of Strategy and Portfolio, where he played a key role in several successful M&A projects and Grünenthal’s entry into the U.S. market. Before joining Grünenthal, he held positions at Takeda, McKinsey & Company, and Novartis. Adams began his career as a resident in cardiology and holds a Medical Doctor degree. He is married and has two children.
Adams will be succeeding Janneke van der Kamp, who will be leaving Grünenthal to pursue an opportunity outside of the company.
Grünenthal is a global leader in pain management and related diseases. The company is known for its science-based and fully integrated approach to developing innovative treatments and state-of-the-art technologies for patients worldwide. Their mission is to change lives for the better, with a focus on innovation. Grünenthal operates in 27 countries across Europe, Latin America, and the U.S. and has products available in approximately 100 countries. As of 2023, the company had around 4,400 employees and achieved revenues of €1.8 billion.
For more information about Grünenthal, please visit their website at https://www.grunenthal.com.
Follow Grünenthal on LinkedIn at Grunenthal Group and on Instagram at grunenthal.
For media inquiries, please contact Florian Dieckmann, Head of Global Corporate Affairs & Communication, at +49 241 569-2555 or via email at Florian.dieckmann@grunenthal.com.
This news was distributed by https://pressat.co.uk/.
![[B-SIDE Podcast] No to war, yes to investments, Filipino-Chinese businessmen say](https://investdailypro.com/wp-content/uploads/2024/09/B-Side-Lamoiyan-Art-300x300-mwOwFT-120x86.jpeg)
